Teva and mAbxience Expand Partnership with New Anti-PD-1 Oncology Biosimilar
核心洞察
Teva (搜索) and mAbxience (搜索) have entered a global licensing agreement to develop an anti-PD-1 oncology (搜索) biosimilar (搜索), marking their second collaboration.
mAbxience (搜索) will handle the biosimilar (搜索)'s development and production in its facilities in Spain and Argentina.
Teva (搜索) will manage regulatory approvals and commercialization in key markets, including Europe and the United States.
Teva (搜索) Pharmaceutical Industries and mAbxience (搜索) have announced an expansion of their partnership with a new global licensing agreement focused on developing an anti-PD-1 oncology (搜索) biosimilar (搜索). This agreement marks the second collaboration between the two companies, building on their initial partnership established in April 2024.
Collaboration Details
mAbxience (搜索) will spearhead the development and production of the biosimilar (搜索), utilizing its cGMP-compliant facilities in Spain and Argentina. Teva (搜索) will manage the regulatory approval process and oversee commercialization in key markets, including Europe and the United States. This strategic alliance leverages the strengths of both companies to enhance the accessibility of critical oncology (搜索) treatments.
Strategic Implications
Angus Grant, Executive Vice President of Business Development at Teva (搜索), emphasized the importance of the collaboration, stating, "This agreement not only strengthens our alliance but also highlights our shared dedication to expanding access to critical oncology (搜索) treatments...This collaboration with mAbxience (搜索) reflects Teva’s ideal strategic partnership model to optimize development costs, apply our regulatory expertise and leverage our extensive commercial capabilities to bring new treatment options to people living with serious medical conditions."
mAbxience's Perspective
Jurgen Van Broeck, CEO of mAbxience (搜索), highlighted the significance of the expanded partnership: "Building on our first agreement with Teva (搜索) signed earlier this year, this second collaboration is a testament to the strength of our partnership and the shared vision of both companies...This agreement reinforces our commitment to making high-quality biosimilars accessible and improving healthcare outcomes on a global scale."
Focus on Accessibility
The collaboration underscores a shared commitment to providing cost-effective, high-quality biosimilar (搜索) treatments to address critical unmet needs in oncology (搜索) care. By leveraging each company’s unique expertise and resources, the partnership aims to drive innovation and accessibility in healthcare, ultimately creating solutions for patients worldwide.